Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature

Rituximab therapy for thrombotic thrombo

Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders

✍ James N. George; Robert D. Woodson; Joseph E. Kiss; Kiarash Kojouri; Sara K. Ves 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract The rationale for immunosuppressive therapy of thrombotic thrombocytopenic purpura (TTP) was established by observations that TTP may be caused by autoantibodies to ADAMTS13. Patients with high‐titer autoantibodies to ADAMTS13 may have a higher mortality, and survivors may require prolo